VEGF-A levels in RP and non-RP eyes

Article

Sufferers of retinitis pigmentosa (RP) have a lower concentration of vascular endothelial growth factor A (VEGF-A) in the aqueous humour than non-sufferers, according to results of a study published in the August 2008 issue of Investigative Ophthalmology and Visual Science.

Sufferers of retinitis pigmentosa (RP) have a lower concentration of vascular endothelial growth factor A (VEGF-A) in the aqueous humour than non-sufferers, according to results of a study published in the August 2008 issue of Investigative Ophthalmology and Visual Science.

David Salom of the Department of Ophthalmology, University General Hospital of Valencia, Valencia, Spain and colleagues conducted a prospective, comparative control study, assessing the levels of VEGF-A in the aqueous humour of RP patients (n=16) through an enzyme-linked immunosorbent assay and comparing them to the levels of VEGF-A in the aqueous humour of otherwise healthy subjects preparing to undergo cataract surgery (n=16).

RP eyes had a mean VEGF-A level of 94.9±99.8 pg/mL; the control group had a mean VEGF-A level of 336.5±116.8 pg/mL.

The researchers observed that the VEGF-A level in non-RP eyes was significantly higher than in RP eyes, and concluded that the lower levels of VEGF-A could be a causative factor in the pathogenesis of RP.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.